- Home
- MYGN vs SLNO Comparison
MYGN vs SLNO Comparison
Compare MYGN & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- SLNO
- Stock Information
- Founded
- MYGN 1991
- SLNO 1999
- Country
- MYGN United States
- SLNO United States
- Employees
- MYGN N/A
- SLNO N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- SLNO Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- MYGN Health Care
- SLNO Health Care
- Exchange
- MYGN Nasdaq
- SLNO Nasdaq
- Market Cap
- MYGN 2.0B
- SLNO 1.9B
- IPO Year
- MYGN 1995
- SLNO 2014
- Fundamental
- Price
- MYGN $13.36
- SLNO $45.18
- Analyst Decision
- MYGN Hold
- SLNO Strong Buy
- Analyst Count
- MYGN 12
- SLNO 6
- Target Price
- MYGN $23.92
- SLNO $74.83
- AVG Volume (30 Days)
- MYGN 942.4K
- SLNO 781.7K
- Earning Date
- MYGN 11-07-2024
- SLNO 11-06-2024
- Dividend Yield
- MYGN N/A
- SLNO N/A
- EPS Growth
- MYGN N/A
- SLNO N/A
- EPS
- MYGN N/A
- SLNO N/A
- Revenue
- MYGN $823,600,000.00
- SLNO N/A
- Revenue This Year
- MYGN $13.82
- SLNO N/A
- Revenue Next Year
- MYGN $4.59
- SLNO N/A
- P/E Ratio
- MYGN N/A
- SLNO N/A
- Revenue Growth
- MYGN 12.15
- SLNO N/A
- 52 Week Low
- MYGN $12.87
- SLNO $35.70
- 52 Week High
- MYGN $29.30
- SLNO $60.92
- Technical
- Relative Strength Index (RSI)
- MYGN 26.22
- SLNO 32.12
- Support Level
- MYGN $12.87
- SLNO $43.32
- Resistance Level
- MYGN $15.44
- SLNO $48.51
- Average True Range (ATR)
- MYGN 0.84
- SLNO 2.09
- MACD
- MYGN -0.02
- SLNO -0.38
- Stochastic Oscillator
- MYGN 12.37
- SLNO 20.44
About MYGN Myriad Genetics Inc.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its product candidates comprise Diazoxide Choline Controlled-Release tablets, which is an oral tablet for the treatment of Prader-Willi Syndrome. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine.